TY - JOUR
T1 - Advance in Plasma AD Core Biomarker Development
T2 - Current Findings from Immunomagnetic Reduction-Based SQUID Technology
AU - Lue, Lih Fen
AU - Kuo, Yu Min
AU - Sabbagh, Marwan
N1 - Funding Information:
The authors are supported by State of Arizona funding ADHS Grant no. ADHS14-052688 (Lue), and National Institute on Aging, 5P20GM109025 and Keep Memory Alive Foundation (Sabbagh). No funding or sponsorship was received for this study or publication of this article. We thank Douglas G. Walker, Ph.D. for English editing of this manuscript (http://www.expertsciencewriting.com ). All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Lue: the author has served as a technical consultant for MagQu, Ltd. (Oct 2018–Feb 2019). She has no proprietary interest in the investigational products or of the company. Kuo: no conflict of interest. Sabbagh: the author served as an investigator in the biomarker development plan. He has no proprietary interest in the investigational products or of the company. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Funding Information:
The authors are supported by State of Arizona funding ADHS Grant no. ADHS14-052688 (Lue), and National Institute on Aging, 5P20GM109025 and Keep Memory Alive Foundation (Sabbagh). No funding or sponsorship was received for this study or publication of this article.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.
AB - New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.
UR - http://www.scopus.com/inward/record.url?scp=85076344266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076344266&partnerID=8YFLogxK
U2 - 10.1007/s40120-019-00167-2
DO - 10.1007/s40120-019-00167-2
M3 - Review article
AN - SCOPUS:85076344266
SN - 2193-8253
VL - 8
SP - 95
EP - 111
JO - Neurology and Therapy
JF - Neurology and Therapy
ER -